Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction

International Wound Journal

Volumn 14, Issue 1, 2017, Pages 214-225

  Ojalvo, Ariana García ^a   Acosta, Jorge Berlanga ^a   Marí, Yssel Mendoza ^a   Mayola, Maday Fernández ^a   Pérez, Calixto Valdés ^b   Gutiérrez, William Savigne ^b   Marichal, Ileydis Iglesias ^c   Seijas, Eduardo Álvarez ^c   Kautzman, Alicia Molina ^a   Pacheco, Angélica Estrada ^a   Armstrong, David G ^d  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Pathology Department   (Cuba)

^c National Center for Integral Diabetes Care   (Cuba)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; Diabetes complications; Diabetic foot ulcers; Epidermal growth factor; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; EPIDERMAL GROWTH FACTOR; GELATINASE B; INTERSTITIAL COLLAGENASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; GRANULATION TISSUE; HUMAN; LIPID PEROXIDATION; MALE; OUTCOME ASSESSMENT; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; WOUND HEALING; AGED; CUBA; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CUBA; DIABETIC FOOT; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; WOUND HEALING;

EID: 84961801339     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/iwj.12592     Document Type: Article

References (67)

1. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058–70.
2. Berlanga-Acosta J, Schultz GS, Lopez-Mola E, Guillen-Nieto G, Garcia-Siverio M, Herrera-Martinez L. Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing. BioMed Res Int 2013;2013:256043.
3. Maier HM, Ilich JZ, Kim JS, Levenson CW, Arjmandi BH, Spicer MT. Dietary advanced glycation end-products exacerbate oxidative stress in patients with diabetic foot ulcers. J Diabetes Res Clin Met 2014;3. DOI: 10.7243/2050-0866-3-2.
4. Morbach S, Furchert H, Groblinghoff U, Hoffmeier H, Kersten K, Klauke GT, Klemp U, Roden T, Icks A, Haastert B, Rumenapf G, Abbas ZG, Bharara M, Armstrong DG. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care 2012;35:2021–7.
5. Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007;4:286–7.
6. Dhall S, Do DC, Garcia M, Kim J, Mirebrahim SH, Lyubovitsky J, Lonardi S, Nothnagel EA, Schiller N, Martins-Green M. Generating and reversing chronic wounds in diabetic mice by manipulating wound redox parameters. J Diabetes Res 2014;2014:562625.
7. Armstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol 2011;5:1591–5.
8. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719–24.
9. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366:1736–43.
10. Thomson SE, McLennan SV, Twigg SM. Growth factors in diabetic complications. Expert Rev Clin Immunol 2006;2:403–18.
11. Kasayama S, Ohba Y, Oka T. Epidermal growth factor deficiency associated with diabetes mellitus. Proc Natl Acad Sci U S A 1989;86:7644–8.
12. Portero-Otin M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, Negre-Salvayre A. Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes 2002;51:1535–42.
13. Berlanga-Acosta J, Gavilondo-Cowley J, Lopez-Saura P, Gonzalez-Lopez T, Castro-Santana MD, Lopez-Mola E, Guillen-Nieto G, Herrera-Martinez L. Epidermal growth factor in clinical practice—a review of its biological actions, clinical indications and safety implications. Int Wound J 2009;6:331–46.
14. Buckley A, Davidson JM, Kamerath CD, Wolt TB, Woodward SC. Sustained release of epidermal growth factor accelerates wound repair. Proc Natl Acad Sci U S A 1985;82:7340–4.
15. Berlanga-Acosta J. Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. Int Wound J 2011;8:612–20.
16. Yera-Alos IB, Alonso-Carbonell L, Valenzuela-Silva CM, Tuero-Iglesias AD, Moreira-Martinez M, Marrero-Rodriguez I, Lopez-Mola E, Lopez-Saura PA. Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. BMC Pharmacol Toxicol 2013;14:44.
17. Lopez-Saura PA, Yera Alos IB, Valenzuela-Silva C, Gonzalez-Diaz O, Del Rio-Martin A, Berlanga-Acosta J, Fernandez-Montequin JI, Acevedo-Castro B, Lopez-Mola E, Herrera-Martinez L. Medical practice confirms clinical trial results of the use of intralesional human recombinant epidermal growth factor in advanced diabetic foot ulcers. Adv Pharmacoepidemiol Drug Saf 2013;2:128.
18. Berlanga J, Prats P, Remirez D, Gonzalez R, Lopez-Saura P, Aguiar J, Ojeda M, Boyle JJ, Fitzgerald AJ, Playford RJ. Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. Am J Pathol 2002;161:373–9.
19. Caballero ME, Berlanga J, Ramirez D, Lopez-Saura P, Gozalez R, Floyd DN, Marchbank T, Playford RJ. Epidermal growth factor reduces multiorgan failure induced by thioacetamide. Gut 2001;48:34–40.
20. Hu ZX, Chen CL, Yang JS, Zhou ZL, Song ZM, Wang ZY. PI3K-mediated glioprotective effect of epidermal growth factor under oxidative stress conditions. Int J Ophthalmol 2014;7:413–20.
21. Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 1981;2:64–122.
22. Mills JL Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, Andros G. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014;59:220–34.
23. Zhan LX, Branco BC, Armstrong DG, Mills JL Sr. The Society for Vascular Surgery lower extremity threatened limb classification system based on wound, ischemia, and foot infection (WIfI) correlates with risk of major amputation and time to wound healing. J Vasc Surg 2015;61:939–44.
24. Armstrong DG, Lavery LA, Nixon BP, Boulton AJ. It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound. Clin Infect Dis 2004;39:S92–9.
25. Martinez A, Lopez LD, Perez R, Anton J, Agüero MM, Peon O, Taquechel L, de Cespedes V, Perez L, Martinez E, Dominguez F, Ung-Lau EV, Hernandez F, Gonzalez T, Lopez-Saura P. Uso del Factor de Crecimiento Epidérmico humano recombinante en crema de sulfadiacina de plata en el tratamiento de pacientes quemados. Biotecnol Apl 1994;11:209–12.
26. Reynolds TM, Smellie WS, Twomey PJ. Glycated haemoglobin (HbA1c) monitoring. BMJ 2006;333:586–8.
27. Armstrong DG, Mills JL. Toward a change in syntax in diabetic foot care: prevention equals remission. J Am Podiatr Med Assoc 2013;103:161–2.
28. Cinza AM, Quintana M, Lombardero J, Poutou R, Pérez E, Pérez LC, Mella CM, Besada V, Padrón G, Castellanos L, Estrada R, Morales-Grillo J. A batch process for production of human Epidermal Growth Factor in yeast. Product characterization. Biotecnología Aplicada 1991;8:166–73.
29. Berlanga J, Fernandez JI, Lopez E, Lopez PA, del RA, Valenzuela C, Baldomero J, Muzio V, Raices M, Silva R, Acevedo BE, Herrera L. Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev 2013;15:11–15.
30. Lopez-Saura PA, Berlanga-Acosta J, Fernandez-Montequin JI, Valenzuela-Silva C, Gonzalez-Diaz O, Savigne-Gutierrez W, Morejon-Vega L, Del Rio-Martin A, Herrera-Martinez L, Lopez-Mola E, Acevedo-Castro B. Intralesional human recombinant epidermal growth factor for the treatment of advanced diabetic foot ulcer: from proof of concept to confirmation of the efficacy and safety of the procedure. 2011:217–38. DOI: 10.5772/28150.
31. Schultz GS, Sibbald RG, Falanga V, Ayello EA, Dowsett C, Harding K, Romanelli M, Stacey MC, Teot L, Vanscheidt W. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen 2003;11(Suppl 1):S1–28.
32. Valenzuela-Silva CM, Tuero-Iglesias AD, Garcia-Iglesias E, Gonzalez-Diaz O, Del Rio-Martin A, Yera Alos IB, Fernandez-Montequin JI, Lopez-Saura PA. Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor. Diabetes Care 2013;36:210–15.
33. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82:291–5.
34. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–25.
35. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999;13:23–30.
36. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003;112:1049–57.
37. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011;46:217–24.
38. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599–622.
39. Kopprasch S, Srirangan D, Bergmann S, Graessler J, Schwarz PE, Bornstein SR. Association between systemic oxidative stress and insulin resistance/sensitivity indices—the PREDIAS study. Clin Endocrinol (Oxf) 2015.
40. Gordillo GM, Sen CK. Revisiting the essential role of oxygen in wound healing. Am J Surg 2003;186:259–63.
41. Rodriguez PG, Felix FN, Woodley DT, Shim EK. The role of oxygen in wound healing: a review of the literature. Dermatol Surg 2008;34:1159–69.
42. Bolajoko EB, Mossanda KS, Adeniyi F, Akinosun O, Fasanmade A, Moropane M. Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer. S Afr Med J 2008;98:614–17.
43. Rattan R, Nayak D. High levels of plasma malondialdehyde, protein carbonyl, and fibrinogen have prognostic potential to predict poor outcomes in patients with diabetic foot wounds: a preliminary communication. Int J Low Extrem Wounds 2008;7:198–203.
44. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 2011;50:567–75.
45. Vicens-Zygmunt V, Estany S, Colom A, Montes-Worboys A, Machahua C, Sanabria AJ, Llatjos R, Escobar I, Manresa F, Dorca J, Navajas D, Alcaraz J, Molina-Molina M. Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices. Respir Res 2015;16:82.
46. Oyewole AO, Birch-Machin MA. Mitochondrial-targeted antioxidants. FASEB J 2015.
47. Mikhed Y, Daiber A, Steven S. Mitochondrial oxidative stress, mitochondrial DNA damage and their role in age-related vascular dysfunction. Int J Mol Sci 2015;16:15918–53.
48. Cai A, Li G, Chen J, Li X, Wei X, Li L, Zhou Y. Glycated hemoglobin level is significantly associated with the severity of coronary artery disease in non-diabetic adults. Lipids Health Dis 2014;13:181.
49. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008;7:29.
50. Ceriello A. Hypothesis: the “metabolic memory”, the new challenge of diabetes. Diabetes Res Clin Pract 2009;86:S2–6.
51. Morales S, Garcia-Salcedo JA, Munoz-Torres M. Pentosidine: a new biomarker in diabetes mellitus complications. Med Clin (Barc) 2011;136:298–302.
52. Kerkeni M, Saidi A, Bouzidi H, Letaief A, Ben YS, Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res 2013;10:239–45.
53. Miyata T, Maeda K, Kurokawa K, van Ypersele de SC. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997;12:255–8.
54. Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 2002;92:12–18.
55. Berlanga-Acosta J, Valdes-Perez C, Savigne-Gutierrez W, Mendoza-Mari Y, Franco-Perez N, Vargas-Machiran E, Poll-Marrón N, Alvarez-Duarte H, Echeverria-Requeijo H, Pérez-Aguilar RM. Cellular and molecular insights into the wound healing mechanism in diabetes. Biotecnol Apl 2010;27:255–61.
56. Li Z, Guo S, Yao F, Zhang Y, Li T. Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers. J Diabetes Complications 2013;27:380–2.
57. Fernandez-Montequin JI, Infante-Cristia E, Valenzuela-Silva C, Franco-Perez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejon-Vega L, Gonzalez-Benavides C, Eliseo-Musenden O, Garcia-Iglesias E, Berlanga-Acosta J, Silva-Rodriguez R, Betancourt BY, Lopez-Saura PA. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007;4:333–43.
58. Fernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernandez F, Sanchez-Penton P, Morejon-Vega L, Artaza-Sanz H, Garcia-Herrera A, Gonzalez-Benavides C, Hernandez-Canete CM, Vazquez-Proenza A, Berlanga-Acosta J, Lopez-Saura PA. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J 2009;6:432–43.
59. Fernandez-Montequin JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galan-Naranjo K, Ramirez-Navas M, Bermudez-Rojas S, Rosales F, Garcia-Iglesias E, Berlanga-Acosta J, Silva-Rodriguez R, Garcia-Siverio M, Martinez LH. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J 2009;6:67–72.
60. Berlanga-Acosta J, Mendoza-Mari Y, Martinez MD, Valdes-Perez C, Ojalvo AG, Armstrong DG. Expression of cell proliferation cycle negative regulators in fibroblasts of an ischemic diabetic foot ulcer. A clinical case report. Int Wound J 2013;10:232–6.
61. Berlanga-Acosta J, Armstrong DG, Schultz GS, Herrera-Martinez L. Chronic wounds with emphasis in diabetic foot ulcers. Biomed Res Int 2014;2014:890352.
62. Berlanga-Acosta J, Gavilondo-Cowley J, Garcia del Barco-Herrera D, Martin-Machado J, Guillen-Nieto G. Epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and tumor progression. J Carcinog Mutagen 2011;2. DOI: 10.4172/2157-2518.1000115.
63. Berlanga J, Caballero E, Prats P, Lopez SP, Playford RJ. The role of the epidermal growth factor in cell and tissue protection. Med Clin (Barc) 1999;113:222–9.
64. Qin XQ, Sun XH, Lou ZQ, Guan CX, Zhang CQ. Cytoprotective effect of epidermal growth factor on cultured rabbit airway epithelial cells exposed to ozone. Sheng Li Xue Bao 1996;48:190–4.
65. Arda-Pirincci P, Bolkent S. The role of epidermal growth factor in prevention of oxidative injury and apoptosis induced by intestinal ischemia/reperfusion in rats. Acta Histochem 2014;116:167–75.
66. Kalay Z, Cevher SC. Oxidant and antioxidant events during epidermal growth factor therapy to cutaneous wound healing in rats. Int Wound J 2012;9:362–71.
67. Acosta JB, del Barco DG, Vera DC, Savigne W, Lopez-Saura P, Guillen NG, Schultz GS. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J 2008;5:530–9.